Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. Circulating elements have gained significant interest in the diagnosis and prognosis of NSCLC patients. Among these, platelets (PLTs) and their derived extracellular vesicles (P-EVs) are emerging eligible biosources both in terms of number and carriers of genetic materials (RNA, proteins, and lipids). PLTs are mainly produced by the shedding of megakaryocytes and together with P-EVs, participate in a variety of pathological processes including thrombosis, tumor progression, and metastasis. Here, we performed an extensive literature review focusing on PLTs and P-EVs as potential diagnostic, prognostic, and predictive markers for NSCLC patient management.

Automated summary

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. Circulating elements such as platelets (PLTs) and their derived extracellular vesicles (P-EVs) have potential as diagnostic, prognostic, and predictive markers for NSCLC patient management. PLTs and P-EVs are both carriers of genetic materials and are involved in various pathological processes related to thrombosis, tumor progression, and metastasis.